# Dupilumab Therapy in Nephrotic Syndrome in Children

> **NCT07091175** · PHASE2 · RECRUITING · sponsor: **National University Hospital, Singapore** · enrollment: 66 (estimated)

## Conditions studied

- Nephrotic Syndrome in Children
- Nephrotic Syndrome Steroid-Dependent

## Interventions

- **BIOLOGICAL:** Dupilumab
- **DRUG:** Placebo
- **DRUG:** Co-intervention of Prednisolone wean during randomised controlled phase
- **BIOLOGICAL:** Dupilumab open label extension phase
- **DRUG:** Co-intervention of Prednisolone wean during open label extension phase

## Key facts

- **NCT ID:** NCT07091175
- **Lead sponsor:** National University Hospital, Singapore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-27
- **Primary completion:** 2028-02-28
- **Final completion:** 2028-02-28
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-12-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07091175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07091175, "Dupilumab Therapy in Nephrotic Syndrome in Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07091175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*